130 related articles for article (PubMed ID: 30346496)
1. Positively Framed Risk Information in Patient Information Leaflets Reduces Side Effect Reporting: A Double-Blind Randomized Controlled Trial.
Webster RK; Weinman J; Rubin GJ
Ann Behav Med; 2018 Oct; 52(11):920-929. PubMed ID: 30346496
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Positively Framing Side-Effect Risk in Two Different Formats on Side-Effect Expectations, Informed Consent and Credibility: A Randomised Trial of 16- to 75-Year-Olds in England.
Webster RK; Rubin GJ
Drug Saf; 2020 Oct; 43(10):1011-1022. PubMed ID: 32557180
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Side Effect Information Framing on Nocebo Effects.
Faasse K; Huynh A; Pearson S; Geers AL; Helfer SG; Colagiuri B
Ann Behav Med; 2019 Jun; 53(7):621-629. PubMed ID: 30204841
[TBL] [Abstract][Full Text] [Related]
4. Nocebo effects of a simplified package leaflet compared to unstandardised oral information and a standard package leaflet: a pilot randomised controlled trial.
Prediger B; Meyer E; Büchter R; Mathes T
Trials; 2019 Jul; 20(1):458. PubMed ID: 31349865
[TBL] [Abstract][Full Text] [Related]
5. Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials.
Kirby N; Shepherd V; Howick J; Betteridge S; Hood K
Trials; 2020 Jul; 21(1):658. PubMed ID: 32680561
[TBL] [Abstract][Full Text] [Related]
6. Predicting Expectations of Side-Effects for Those Which Are Warned Versus Not Warned About in Patient Information Leaflets.
Webster RK; Rubin GJ
Ann Behav Med; 2021 Nov; 55(12):1253-1261. PubMed ID: 33821932
[TBL] [Abstract][Full Text] [Related]
7. Using Positive Attribute Framing to Attenuate Nocebo Side Effects: A Cybersickness Study.
Mao A; Barnes K; Sharpe L; Geers AL; Helfer SG; Faasse K; Colagiuri B
Ann Behav Med; 2021 Jul; 55(8):769-778. PubMed ID: 33674858
[TBL] [Abstract][Full Text] [Related]
8. Applying behavioural science to increase uptake of the NHS Health Check: a randomised controlled trial of gain- and loss-framed messaging in the national patient information leaflet.
Gold N; Durlik C; Sanders JG; Thompson K; Chadborn T
BMC Public Health; 2019 Nov; 19(1):1519. PubMed ID: 31727030
[TBL] [Abstract][Full Text] [Related]
9. Medicine-related beliefs predict attribution of symptoms to a sham medicine: A prospective study.
Webster RK; Weinman J; Rubin GJ
Br J Health Psychol; 2018 May; 23(2):436-454. PubMed ID: 29405507
[TBL] [Abstract][Full Text] [Related]
10. Utility of patient information leaflet and perceived impact of its use on medication adherence.
Al Jeraisy M; Alshammari H; Albassam M; Al Aamer K; Abolfotouh MA
BMC Public Health; 2023 Mar; 23(1):488. PubMed ID: 36918823
[TBL] [Abstract][Full Text] [Related]
11. Does different information disclosure on placebo control affect blinding and trial outcomes? A case study of participant information leaflets of randomized placebo-controlled trials of acupuncture.
Cheon S; Park HJ; Chae Y; Lee H
BMC Med Res Methodol; 2018 Jan; 18(1):13. PubMed ID: 29347917
[TBL] [Abstract][Full Text] [Related]
12. How (not) to inform patients about drug use: use and effects of negations in Dutch patient information leaflets.
Burgers C; Beukeboom CJ; Sparks L; Diepeveen V
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):137-43. PubMed ID: 25044310
[TBL] [Abstract][Full Text] [Related]
13. Preference of patient information leaflets over standard drug monographs by patients prescribed hydrochlorothiazide, nifedipine and enalapril.
Gossell-Williams M; Bennett O; Dias Y; Foster K; Houston M; Wright K; Fairclough Z
West Indian Med J; 2012 Jun; 61(3):271-9. PubMed ID: 23155986
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial of patient information leaflets as a medication counselling aid.
McNeill R; Chin P; Coberger E; Doogue M
Intern Med J; 2019 Mar; 49(3):328-332. PubMed ID: 30022574
[TBL] [Abstract][Full Text] [Related]
15. Retention strategies are routinely communicated to potential trial participants but often differ from what was planned in the trial protocol: an analysis of adult participant information leaflets and their corresponding protocols.
Murphy E; Gillies K; Shiely F
Trials; 2024 Jun; 25(1):372. PubMed ID: 38858790
[TBL] [Abstract][Full Text] [Related]
16. How does the side-effect information in patient information leaflets influence peoples' side-effect expectations? A cross-sectional national survey of 18- to 65-year-olds in England.
Webster RK; Weinman J; Rubin GJ
Health Expect; 2017 Dec; 20(6):1411-1420. PubMed ID: 28618140
[TBL] [Abstract][Full Text] [Related]
17. The effect of how outcomes are framed on decisions about whether to take antihypertensive medication: a randomized trial.
Carling CL; Kristoffersen DT; Oxman AD; Flottorp S; Fretheim A; Schünemann HJ; Akl EA; Herrin J; MacKenzie TD; Montori VM
PLoS One; 2010 Mar; 5(3):e9469. PubMed ID: 20209127
[TBL] [Abstract][Full Text] [Related]
18. The OMACS-PIL study: a randomised controlled trial within the OMACS observational study.
Culliford L; Brierley R; Clout M; Evans R; Maishman R; Phillips D; Tabusa H; Reeves B; Rogers CA
Trials; 2019 Dec; 20(1):772. PubMed ID: 31881927
[TBL] [Abstract][Full Text] [Related]
19. Using short information leaflets as recruitment tools did not improve recruitment: a randomized controlled trial.
Brierley G; Richardson R; Torgerson DJ
J Clin Epidemiol; 2012 Feb; 65(2):147-54. PubMed ID: 21889304
[TBL] [Abstract][Full Text] [Related]
20. Health complaints and wind turbines: The efficacy of explaining the nocebo response to reduce symptom reporting.
Crichton F; Petrie KJ
Environ Res; 2015 Jul; 140():449-55. PubMed ID: 25981871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
